March 17th 2023
In separate live, virtual events, Ulka N. Vaishampayan, MBBS, and David A. Braun, MD, PhD, discussed options for a patient with favorable-risk clear cell renal cell carcinoma.
Cabozantinib and Immunotherapy Combination Improves Efficacy in Advanced Renal Cell Cancer SubgroupsFebruary 18th 2023
Cabozantinib improved outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among poor-risk patients in combination with nivolumab and ipilimumab.
Cabozantinib Therapy Shows Early Efficacy in Advanced RCC After Checkpoint Inhibitor CombonationFebruary 18th 2023
Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.
CheckMate-9ER Data Continues to Show Benefit With Nivolumab + Cabozantinib in RCCFebruary 14th 2023
Nivolumab plus cabozantinib led to superior overall survival, progression-free survival, overall response, duration of response, and complete response rates vs sunitinib in patients with advanced renal cell carcinoma.
Opinions on the Optimal Role of Ipilimumab/Nivolumab in RCCFebruary 13th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Alan Tan, MD, discussed with participants their experiences with frontline regimens for advanced renal cell carcinoma, and potential trials that could optimize the use of immunotherapy and tyrosine kinase inhibitors. This is the second of 2 articles based on this event.
Park Discusses Results of Multiple Phase 3 Trials in ccRCCFebruary 7th 2023
During a Targeted Oncology case-based roundtable discussion, Chandler Park, MD, discussed the trials that led to the approval of frontline combination regimens for patients with advanced clear cell renal cell carcinoma.
Beckermann on Recent Data and Hopes for the Evolving RCC LandscapeFebruary 2nd 2023
In an interview with Targeted Oncology, Kathryn Beckermann, MD, PhD, discussed her talk from the International Kidney Cancer Symposium: North America 2022 on risk stratifications and considerations for improving outcomes for patients with renal cell carcinoma.
Managing Frontline Toxicities in Patients With RCCFebruary 1st 2023
During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed with participants their experiences managing toxicities of frontline combination therapy for renal cell carcinoma. This is the second of 2 articles based on this event.
Physicians Discuss Potential of Frontline Triplet Regimens for RCCJanuary 27th 2023
During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.
Early Promise Is Seen With CTX130 for RCCJanuary 18th 2023
According to findings from the phase 1 COBALT-RCC trial, CTX130 led to an objective response rate of 8%, a stable disease rate of 69%, and a disease control rate of 77% in patients with advanced clear cell renal cell carcinoma.
Vaishampayan Reviews Frontline IO/TKI Regimens for Favorable-Risk ccRCCJanuary 12th 2023
During a Targeted Oncology case-based roundtable event, Ulka N. Vaishampayan, MBBS, discussed the frontline combination regimens available for a patient with favorable risk clear cell renal cell carcinoma.
IO/IO Versus IO/TKI Frontline Therapy for Intermediate-Risk RCCJanuary 11th 2023
During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed the factors influencing the choice of frontline therapy for a patient with stage IV clear cell renal cell carcinoma whose risk status was intermediate.
Factors Favoring Tivozanib as Third-Line Therapy for Advanced RCCJanuary 2nd 2023
During a Targeted Oncology case-based roundtable event, Saby George, MD, and participants discussed the role of tivozanib and other later-line options in patients with advanced renal cell carcinoma.
Second-Line Considerations After Immune Toxicity From Prior RCC TherapyDecember 21st 2022
During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.
Roundtable Discussion: McKay Covers First-Line Decision-Making for Metastatic RCCDecember 20th 2022
During a Targeted Oncology case-based roundtable event, Rana McKay, MD, and participants discussed the case of a patient with previously untreated advanced renal cell carcinoma with favorable risk status.
Cabozantinib/Nivolumab Appears Safe Up to 14 Days Before Cytoreductive Nephrectomy in RCCNovember 19th 2022
In an interview with Targeted Oncology, Karie Runcie, MD, provided an assessment on the Clavien-Dindo classification system and discussed initial results of the Cyo-KIK trial.
Current and Potential Second-Line Therapies Following IO/TKI in RCCNovember 11th 2022
Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.
Tivozanib Shows Efficacy and Tolerability in Non-Clear Cell RCCNovember 10th 2022
Retrospective analysis of a phase 2 trial indicated that tivozanib demonstrated efficacy and tolerability in the subset of patients who had non-clear cell histologies of renal cell carcinoma.
Reviewing Efficacy and Tolerability in TIVO-3 Trial of Tivozanib for RCCNovember 8th 2022
During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed the results of the TIVO-3 trial of tivozanib. This is the second of 2 articles based on this event.